March 28, 2017
February 28, 2017
Harvard Business Review
February 23, 2017
InVivo Therapeutics Announces New Site for INSPIRE Study
April 10, 2017
“We at InVivo are very excited to have announced that Health Canada has approved the company’s Investigational Testing Authorization application to commence a clinical study in patients with acute, complete (AIS A) cervical spinal cord injuries in Canada. These patients are the most severely injured of all SCI patients and any neurological improvement could make a significant difference in their quality of life. As compared to the thoracic spinal cord, the cervical spinal cord represents a region of higher risk and higher potential reward, since each level of this region has substantial functional impact. ” For full text, click here.
Mark Perrin, CEO and Chairman, 3/23/2017